Claims
- 1. 1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-one having the formula ##STR4## or a pharmaceutically acceptable acid-addition or cationic salt thereof, where R is lower-alkyl, R' is hydrogen or methyl, R" is hydrogen or lower-alkyl, and Q is hydrogen, hydroxy or amino.
- 2. A compound according to claim 1 where R is methyl, ethyl or propyl, R' and R" are each hydrogen, and Q is hydrogen, hydroxy or amino.
- 3. 5-Methyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 4. 5-Ethyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 5. 5-n-Propyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 6. 3-Hydroxy-5-methyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 7. 3-Amino-5-methyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 8. 1,5-Dimethyl-1,6-naphthyridin-2(1H)-one according to claim 1.
- 9. A cardiotonic composition for increasing cardiac contractility which comprises a pharmaceutically acceptable carrier and, as the active component thereof, a cardiotonically effective amount of the 1-R"-3-Q-4-R'-R-1,6-naphthyridin-2(1H)-one of claim 1 or pharmaceutically acceptable acid-addition or cationic salt thereof, where R, R' and R" have the meanings given in claim 1, and Q is hydrogen, hydroxy or amino.
- 10. A cardiotonic composition according to claim 9 where in the active component R is methyl, ethyl or propyl,
- R' and R" are each hydrogen, and Q is hydrogen, hydroxy or amino.
- 11. A cardiotonic composition according to claim 9 where the active component is 5-methyl-1,6-naphthyridin-2(1H)-one.
- 12. A cardiotonic composition according to claim 9 where the active component is 5-ethyl-1,6-naphthridin-2(1H)-one.
- 13. A cardiotonic composition according to claim 9 where the active component is 5-n-propyl-1,6-naphthyridin-2(1H)-one.
- 14. A method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient a cardiotonically effective amount of the 1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-one of claim 1 or 1,6-naphthyridin-2(1H)-one or pharmaceutically acceptable acid-addition or cationic salt thereof, where R, R' and R" have the meanings given in claim 1 and Q is hydrogen, hydroxy or amino.
- 15. A method according to claim 14 where in the active component R is methyl, ethyl or propyl, R' and R" are each hydrogen, and Q is hydrogen, hydroxy or amino.
- 16. A method according to claim 14 where the active component is 5-methyl-1,6-naphthyridin-2(1H)-one.
- 17. A method according to claim 14 where the active component is 5-ethyl-1,6-naphthyridin-2(1H)-one.
- 18. A method according to claim 14 where the active component is 5-n-propyl-1,6-naphthyridin-2(1H) one.
- 19. 1,2-Dihydro-5,6-dimethyl-2-oxo-1,6-naphthyridinium 4-methylbenzenesulfonate.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of copending application Ser. No. 404,454, filed Aug. 2, 1982 and now U.S. Pat. No. 4,415,580, issued Nov. 15, 1983.
Non-Patent Literature Citations (5)
Entry |
Chemical Abstracts 72, 12,615d (1970). |
Ogata et al., [Chem. Pharm. Bull. 20, 2264 (1972)]. |
Hawes et al., [J. Med. Chem. 16, 849 (1973)]. |
Hawes et al., [J. Heterocycl. Chem. 11, 151 (1974)]. |
Moller et al., [Ann. 612, 153 (1957)]. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
404454 |
Aug 1982 |
|